ArticleNature communications2026
Membrane-anchored DNA nanodevice with allosteric aptamer arms enables parallel probing and on-site drug delivery.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
DNA-based molecular computation enables targeting of cells via multiple surface receptors. However, existing platforms are often limited to single-receptor detection per operation or rely on freely diffusing components, a common source of off-target interference. Here we show an intelligent DNA nanodevice (DND) that integrates multivalent recognition, logic‑gated computation, and spatially precise drug delivery in a single nanostructure. The DND comprises a doxorubicin-loaded tetrahedral DNA framework (tFNA@Dox) connected via three allosteric aptamer arms to a cholesterol-modified membrane anchor. Simultaneous binding of all three aptamers triggers an AND‑logic gate, releasing tFNA@Dox specifically at the target cell membrane. This localized sense‑and‑act mechanism maximizes therapeutic specificity and minimizes systemic exposure. In tumor-bearing mice, DND@Dox effectively accumulated in tumors, significantly inhibited tumor growth under local and systemic administration, and reduced systemic toxicity. This work establishes a versatile platform for logic‑controlled, multimarker‑guided cancer theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.